Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Breast Neoplasms × Fulvestrant × Clear all

Phase

Phase 2 120 Phase 3 52 Phase 1 45 Phase 1/2 27 Phase 4 6 Phase EARLY_PHASE1 2 Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

The Neoadjuvant Therapy 1 Neoplasms 1 Neoplasm Metastasis 1 Hormone Receptor Positive HER-2 Negative Breast Cancer 1 Cholangiocarcinoma 1 Breast Neoplasms 1

Interventions

Capecitabine 13 Paclitaxel 9 Cyclophosphamide 9 Docetaxel 8 Epirubicin 7 Gemcitabine 5 Doxorubicin 5 Trastuzumab 4 Letrozole 4 Carboplatin 4 pertuzumab 3 exemestane 3 Vinorelbine 3 AC protocol 3 Thiotepa 2 Taxes 2 Neoadjuvant Therapy 2 Melatonin 2 Lapatinib 2 Fluorouracil 2 Drug Therapy 2 Cisplatin 2 Albumin-Bound Paclitaxel 2 Ado-Trastuzumab Emtansine 2 130-nm albumin-bound paclitaxel 2 taxane 1 soluble LAG-3 protein, human 1 pyrotinib 1 pitavastatin 1 palbociclib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04191499 2026-03-17

INAVO120

Hoffmann-La Roche

Phase 2/3 Active not recruiting

325 enrolled 14 charts 1 FDA

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡